(Q38878899)

7 September 2017

1 reference

title

Immune checkpoint inhibitors side effects and management (English)

1 reference

7 September 2017

author

Hampig Raphael Kourie

series ordinal

object named as

Hampig Raphael Kourie

1 reference

7 September 2017

Jean Klastersky

1 reference

7 September 2017

publication date

1 June 2016

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

799-807

1 reference

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Anticancer therapy with checkpoint inhibitors: what, where and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Systematic review: colitis associated with anti-CTLA-4 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Adverse events of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0029

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0029

1 reference

7 September 2017

1 reference